T1	Participants 261 284	healthy adult subjects.
T2	Participants 49 89	antihistaminic (H1) effect of bilastine.
T3	Participants 387 522	In the single-dose studies, a total of 183 subjects received oral doses of bilastine 2.5, 5, 10, 20, 50, 100, 120, 160, 200 and 220 mg.
T4	Participants 523 687	In the multiple-dose studies, 127 healthy subjects received bilastine 10, 20, 40, 50, 80, 100, 140 or 200 mg/day as multiple doses during a 4-, 7- or 14-day period.
T5	Participants 3347 3409	Pharmacokinetic and pharmacodynamic relationships of bilastine
